UK Life Sciences and Healthcare Newsletter: Life Sciences: What's new in France? The Santen case and the notion of second medical use with regards to supplementary protection certificates (SPC): a strict interpretation of the EU regulation

Published date28 January 2021
Subject MatterPatents,Life Sciences,EU,Supplementary Protection Certificate,Pharmaceutical Patents,France,Intellectual Property Protection,CJEU
AuthorMarie Fillon,Louis de Chezelles
Law FirmDechert LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT